Merger arbitrage explained

What merger arbitrage is (and how it differs from pairs trading)

Merger arbitrage is an event-driven strategy that profits from the gap between a target company's market price and the value implied by a announced acquisition, betting the deal will close at or above the offer. It is one branch of event-driven investing alongside distressed debt, spin-offs, and activist situations.

Unlike pairs trading, which hunts statistical relationships between two unrelated stocks, merger arb ties returns to a specific corporate contract with a defined timeline, shareholder vote, and regulatory path. Returns are idiosyncratic: two healthcare mergers in the same quarter can have opposite outcomes based on FTC posture, not sector beta.

The strategy is structurally short volatility and short uncertainty. When deal risk rises (antitrust pushback, financing stress), spreads widen and arb books mark down. In market crashes unrelated to M&A, spreads can paradoxically tighten as acquirers with committed financing look like safe havens — but broken deals in the same period dominate drawdowns.

Deal spread math: gross return, annualization, and probability

For a fixed cash offer, the gross spread is:

Spread = Offer price − Target market price

If the target trades at $39.10 against a $42.00 cash bid expected to close in 150 days, gross return is 7.4%. Annualized (ignoring dividends and financing):

Annualized ≈ (Spread / Price) × (365 / Days to close)

That works out to roughly 18% annualized — attractive until you haircut for probability of completion. Sophisticated desks model:

• Expected value — P(close) × Spread − P(break) × Loss if break
• Scenario tree — base close, delayed close with wider financing cost, break, topping bid from rival.
• Implied probability — reverse-engineer what the market prices from the spread versus a risk-free rate and historical break rates for similar deal types.

Wide spreads are not free money; they usually signal elevated deal-break risk or long closing timelines that tie up capital. A 15% gross spread on a friendly cash deal often means the street sees regulatory or vote problems, not mispricing.

Cash, stock, and mixed deals: how structure changes the trade

All-cash offers

The arb position is typically long the target only. Payoff at close is the spread; downside on break is the fall from deal-announcement levels (often 20–40% for strategic buyers, more for financial sponsors where the premium was the entire thesis).

Stock-for-stock (fixed exchange ratio)

The acquirer offers, say, 0.85 of its shares per target share. The implied offer value floats with the acquirer's price:

Implied offer = Exchange ratio × Acquirer price

The classic hedge is long target, short acquirer in the exchange ratio — locking in the spread in dollar terms and stripping market beta. If the acquirer rallies 10% on synergies enthusiasm, both legs move; the spread P&L is isolated. Short borrow availability and locate costs on the acquirer can make the hedge uneconomic on small-cap deals.

Cash plus stock (collars and floats)

Mixed consideration introduces collar mechanics: the exchange ratio may float within bounds if the acquirer price moves beyond a band. Arbs must model ratio adjustments, dividend treatment on both legs, and whether shareholders can elect cash versus stock (proration risk).

Tender offers vs mergers

Tender offers can close faster (20–40 business days if minimum shares tender) but carry odd-lot and proration mechanics. Long-form mergers require proxy filings, shareholder votes, and longer regulatory clocks — different annualized return profiles for the same nominal spread.

What breaks deals: the risk arb diligence map

Merger arb is less about predicting stock prices than predicting legal and political outcomes. The highest-impact break drivers:

• Antitrust and foreign investment review — FTC/DOJ second requests, EU Phase II, CFIUS for sensitive tech. Horizontal overlaps in concentrated industries (airlines, telecom, hospitals) kill deals or force remedies that reprice synergies.
• Financing conditions — LBOs contingent on debt markets. When credit spreads blow out, sponsors walk or retrade at lower prices.
• Shareholder vote failure — especially when institutional holders judge the price inadequate or the board process flawed.
• Material adverse change (MAC) clauses — acquirers invoke MAC to exit after earnings collapses or regulatory shocks. Courts rarely agree, but litigation drags timelines.
• Regulatory remedies — required divestitures that erase the strategic rationale.
• Competing bids — can lift the target above the initial offer (good for longs) or create uncertainty if the first deal terminates without a winner.

Arbs read merger agreements (8-K exhibits), proxy statements, and HSR filing timing. A spread that fails to tighten after an expected regulatory milestone is often the market front-running trouble.

Worked example: Harbor Capital and the MedAxis acquisition

Fictional worked example for illustration.

Acquirer Helix Health announces an all-cash $42.00/share acquisition of MedAxis (MXD), then trading at $39.10. Harbor's event-driven pod sizes a 2.5% book weight.

Entry analysis

• Gross spread: $2.90 (7.4%). Expected close: 5 months (150 days).
• Annualized gross: ~18%. Harbor's internal P(close) = 82% after antitrust counsel review (modest hospital overlap, divestiture of two clinics likely sufficient).
• Break scenario: MXD retraces to $32 (pre-rumor base plus partial recovery) — 18% downside on the long.
• Expected value: 0.82 × 7.4% − 0.18 × 18% ≈ 2.8% net on capital over 5 months — acceptable versus alternatives if portfolio break correlation is managed.

Timeline events

• Month 2: FTC requests additional data; spread widens to $3.40. Harbor holds — remedy still plausible.
• Month 4: Rival bidder CardioCore offers $44 cash. MXD rises to $43.50. Harbor earns ~11% on the long as the first deal is topped — a positive outcome, not the base case.
• Month 5: Helix matches at $45; CardioCore exits. Spread narrows to $0.40. Harbor trims into close, realizing ~14% total return on the position over the life of the trade.

The example shows three arb outcomes: clean close at offer, break loss, and bidding war uplift. Sizing must assume the break path is nonlinear — one failed biotech merger can offset a dozen 3% winners.

Strategy decision table

Portfolio construction and risk management

Professional merger arb books run 30–80 concurrent positions to diversify idiosyncratic break risk. Key controls:

• Single-name limits — 2–4% of NAV is common; biotech and highly leveraged LBO targets often lower.
• Sector and regulator correlation — six healthcare deals in one book share FTC staff and political mood; cap sector exposure.
• Liquidity — if a deal breaks on a Friday, you exit into a gap down. Position size must respect ADV and spread on the target.
• Hedge ratios on stock deals — rebalance when the acquirer moves; ratio drift creates unintended beta.
• Financing cost — leverage amplifies annualized spread but concentrates break losses; match leverage to worst-case drawdown tolerance per position sizing rules.

Some funds buy options overlays (put spreads on the target) to cap break losses — expensive insurance that narrows net expected return but smooths paths.

Common pitfalls

• Annualizing wide spreads without probability — 25% gross on a troubled deal is not 25% expected return.
• Ignoring the break floor — downside is not “give back the spread”; it is often a full premium evaporation.
• Stock deals without hedging — you are long synergies and sector beta, not arb.
• Concentrating in one regulatory theme — all pharma mergers in one year can correlate on a single FDA or FTC chair.
• Chasing retrades lower — a price cut from $42 to $38 may still break if shareholders revolt.
• Missing dividend and record-date mechanics — who receives the acquirer dividend while waiting affects net carry.
• Treating tender offers like certain closes — proration leaves partial positions with odd risk.

Production checklist

• Read the merger agreement: conditions, termination fees, MAC definitions, and specific performance clauses.
• Map the regulatory calendar: HSR filing dates, EU notification, CFIUS if applicable.
• Model P(close), break price, and rival-bid scenarios before sizing.
• For stock deals, verify short locate on acquirer and stress borrow cost.
• Cap single-name and sector weights; stress test simultaneous breaks.
• Track spread tightening vs milestones; widen without news is a red flag.
• Account for dividends, proration, and collar ratio adjustments in P&L.
• Document exit plan for break, retrade, and topped outcomes before entry.
• Reconcile position marks to implied market probability weekly.
• Pair with realistic backtests only for systematic overlays — deal arb is fundamentally discretionary on legal outcomes.

Key takeaways

• Merger arb harvests deal spreads — the gap between target price and offer value until close or break.
• Returns are asymmetric — many small wins, rare large losses when transactions fail.
• Structure dictates the trade — cash is long-only; stock deals need ratio hedges.
• Regulatory and legal diligence dominate — more than chart patterns or sector momentum.
• Diversification across deals is the risk engine — no single spread is safe because the annualized math looks attractive.

Related reading

• Pairs trading explained — statistical mean reversion vs event-driven deal spreads
• Hedge funds explained — where event-driven and merger arb sleeves sit in allocator portfolios
• Risk management and position sizing explained — caps for asymmetric payoff strategies
• Enterprise value explained — how acquirers value targets and structure consideration